Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

Condition:   HER2-Negative Breast Cancer Intervention:   Drug: Pembrolizumab Sponsors:   University of Malaya;   Merck Sharp & Dohme (MSD);   National University Hospital, Singapore;   Clinical Research Malaysia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials